Table 2.

VEGF Protein Levels in U87 Tumors After SU5416 and Dalteparin.

Treatment Group	Number of Tumors	VEGF Mean pg/10 µg Total Protein	SD	t-test Compared with Controls
Controls	15	236	88
SU5416	13	176	108	NS
Dalteparin	15	205	103	NS
SU5416+dalteparin	15	159	94	P=.03

Dalteparin, in combination with SU5416, significantly reduced the VEGF content in tumors compared with controls. The reduction after SU5416 or dalteparin as monotherapy was not statistically significant. There was no statistical difference in VEGF levels between the different treatment groups. The VEGF levels were measured at a tumor volume of 600 mm³.

NS=no significant difference.